Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Industry

Summit's ivonescimab rejected by FDA, closing off near-term US launch in EGFR-mutant lung cancer

The regulator declined to approve the PD-1/VEGF bispecific after HARMONi showed a progression-free survival gain but no statistically significant overall survival benefit, Summit said.

16 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news

Summit Therapeutics will not bring ivonescimab to the US market in previously treated EGFR-mutant lung cancer for now, after the Food and Drug Administration issued a complete response letter for its biologics licence application. The company disclosed the decision on 15 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Summit Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More IndustryAll →